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Abstract
Background: Methamphetamine (METH), an addictive psycho-stimulant drug with euphoric effect is known to
cause neurotoxicity due to oxidative stress, dopamine accumulation and glial cell activation. Here we hypothesized
that METH-induced interference of glucose uptake and transport at the endothelium can disrupt the energy
requirement of the blood-brain barrier (BBB) function and integrity. We undertake this study because there is no
report of METH effects on glucose uptake and transport across the blood-brain barrier (BBB) to date.
Results: In this study, we demonstrate that METH-induced disruption of glucose uptake by endothelium lead to
BBB dysfunction. Our data indicate that a low concentration of METH (20 μM) increased the expression of glucose
transporter protein-1 (GLUT1) in primary human brain endothelial cell (hBEC, main component of BBB) without
affecting the glucose uptake. A high concentration of 200 μM of METH decreased both the glucose uptake and
GLUT1 protein levels in hBEC culture. Transcription process appeared to regulate the changes in METH-induced
GLUT1 expression. METH-induced decrease in GLUT1 protein level was associated with reduction in BBB tight
junction protein occludin and zonula occludens-1. Functional assessment of the trans-endothelial electrical
resistance of the cell monolayers and permeability of dye tracers in animal model validated the pharmacokinetics
and molecular findings that inhibition of glucose uptake by GLUT1 inhibitor cytochalasin B (CB) aggravated the
METH-induced disruption of the BBB integrity. Application of acetyl-L-carnitine suppressed the effects of METH on
glucose uptake and BBB function.
Conclusion: Our findings suggest that impairment of GLUT1 at the brain endothelium by METH may contribute to
energy-associated disruption of tight junction assembly and loss of BBB integrity.
Background
Methamphetamine (METH), a highly addictive drug is a
potent CNS stimulant that produces euphoric effects by
promoting the release of dopamine, serotonin and nore-
pinephrine [1]. METH abuse and trafficking are increas-
ing law enforcement and social health problems in the
United States, particularly in the mid-western states
where the rates of METH users among teenagers (12-17
years) and young adults (18-25 years) are highest in the
country [2]. The escalating problems due to METH
abuse are enormous financial and health burdens to
family and society. The ability of METH to stimulate
the release of dopamine rapidly from dopaminergic neu-
rons in the reward regions of the brain produces intense
euphoric effects [3]. However, acute bingeing and
chronic self-administration paradigms of METH abuse
cause severe neurotoxicity, monoamine deficits,
hyperthermia, cardiac arrhythmia, depression, addiction,
and psychiatric problems due to neuronal damage [4].
Multiple mechanisms of METH-induced neurotoxicity
have been reported including hyperthermia, dopamine
depletion, microglial activation, free radical formation,
intrinsic cell apoptosis, and cytokine production [5,6].
Acute doses of METH produce hyperthermia that signifi-
cantly contributes to neurotoxicity as a result of dopamine
and intracellular METH accumulation [7,8], while chronic
METH abuse causes hypothermia without an associated
dopamine and serotonin depletion [8]. Interestingly,
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of METH triggers the activation of microglia and loss of
neurons in human brain of METH abusers [9,10]. In ani-
mals, METH-induced loss of dopaminergic neurons and
decreases in dopamine levels occur in specific brain
regions [1,11]. Rakic et al. (1989) demonstrated the blood-
brain barrier disruption after chronic amphetamine
administration in guinea pig [12]. Recent review articles
describe the cellular and molecular mechanisms of
METH-induced neurotoxicity as a consequence of oxida-
tive stress, blood-brain barrier breakdown, microgliosis,
and activation of the apoptotic pathway [13,14]. Disrup-
tion of mitochondrial membrane potential transition and
imbalanced oxidative phosphorylation appears to regulate
the oxidative stress condition and the caspase-dependent
apoptosis due to chronic METH abuse [13,14]. METH
abuse is also shown to exert neurotoxic effects by increas-
ing the secretion of pro-inflammatory cytokines IL-6 and
TNF-alpha in the brain [15,16].
In humans it is reported that METH abusers have
severe dilated cardiomyopathy [17]. In an animal model,
Treweek et al. (2007) indicated glycation of endogenous
proteins and production of pro-inflammatory cytokines
as possible unrecognized molecular mechanisms of car-
diovascular disease in chronic METH abusers [18]. In
an in vitro study, METH accelerates the beating rate
and intracellular Ca
2+ oscillation pattern in rat cardio-
myocytes in culture [19]. However, the underlying
mechanisms of METH-elicited cardiovascular dysfunc-
tion are not well understood. In conjunction with cardi-
ovascular damage, METH abuse appears to impair
blood-brain barrier (BBB) vascular function. This
includes brain hyperthermia and BBB breakdown by
METH treatment [20,21]. Recently, Sharma et al. (2009)
and Ramirez et al. (2009) demonstrated the oxidative
damage related BBB disruption and neurotoxicity by
drug of abuse [22,23].
These myriad effects of METH on cardio-neurovascu-
lar function and on astrogliosis-related neurotoxicity
clearly emphasize the importance of the blood and brain
interface. The blood-brain barrier, principally composed
of the brain endothelium tight junction proteins, is a
dynamic interface. BBB function is maintained at the
expense of huge bio-energy consumption. Thus, efficient
uptake and metabolism of glucose by endothelial cells
regulates the selective barrier and the transport system
of the interface. Importantly, the transport of glucose
from the BBB into the brain regulates the energy-
dependent survival of glial and neuronal cells. Brain
endothelial specific glucose transporter protein 1
(GLUT1) facilitates the transport of glucose from the cir-
culation into the brain. Brain endothelial has the highly
glycosylated 55 kDa GLUT1 and the less glycosylated 45
kDa GLUT1 isoforms [24,25]. GLUT1 is localized 11% in
the luminal, 45% in intracellular pool, and 44% in the
abluminal side of the microvessel [26,27].
Here, we hypothesize that impairment of GLUT1 by
METH at the brain endothelium can deprive glucose
uptake, transport and utilization as source of energy
requirement for dynamic BBB function and subsequent
survival of the brain endothelial cells. We also explore
the protective effect of acetyl-L-carnitine (ALC, a regula-
tor of mitochondrial function) for prevention of GLUT1
and BBB damage from METH exposure. The primary
function of ALC is transporting the long-chain fatty acids
into the mitochondria for oxidation to generate ATP and
it also acts as a precursor for neurotransmission. Thus,
ALC is neuroprotective and often refers to as an anti-
oxidant because ALC maintains the functional integrity
of mitochondria by enhancing b-oxidation fatty acids for
energy production [28,29].
Results
Effects of METH on glucose uptake and GLUT1 expression
We first examined the dose-dependent effect of METH
(5 - 500 μM) exposure for 24 hr on glucose uptake by
primary human brain endothelial cell (hBEC) culture.
Our data indicate an insignificant increase in glucose
uptake by hBECs following exposure to 5-20 μMo f
METH. However, the higher concentrations 50-500 μM
of METH dose-dependently decreased the glucose
uptake by hBECs (Figure 1A). There seemed to be a dif-
ferential effect of 20 μM and 200 μM METH on glucose
uptake. We examined the effects of these two METH
concentrations on glucose uptake by hBECs with/
without cytochalasin B (CB, GLUT inhibitor) and acetyl-
L-carnitine (ALC, neuroprotective agent). As expected,
CB inhibited the effect of 20 μM METH and exacer-
bated the decreased rate of glucose uptake by 200 μM
METH, while ALC protected the effect of 200 μM
METH (Figure 1B). Our time-dependent study showed
that 20 μM METH gradually decreased the glucose
uptake by hBECs with exposure time (Figure 1C), sug-
gesting that low concentration of METH may activate
GLUT1 in acute condition but in long-term it impairs
GLUT1 function.
To correlate the glucose uptake results with GLUT1
protein profile, we evaluated the effect of METH on
GLUT1 expression by immunocytochemistry and Wes-
tern blot analyses in primary hBEC cultures. Immunocy-
tochemistry detection indicates a substantial increase in
GLUT1 expression in hBECs by 20 μM METH exposure,
but a considerable decrease in GLUT1 expression by 200
μM METH exposure for 24 hr compared with untreated
cells (Figure 2A a-f). Co-localization of GLUT1 protein
with von Willebrand factor (vWF) indicates an intracellu-
lar localization of GLUT1 protein in brain endothelial
cells. In agreement with immunocytochemical detection,
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GLUT1 protein by 20 μM METH and a significant
decrease in GLUT1 protein by 200 μMM E T He x p o s u r e
compared with controls (Figure 2B). In parallel with
kinetics profile of glucose uptake, exposure of 20 μM
METH gradually decreased GLUT1 protein levels in
hBECs for longer exposure, which validated the acute
and chronic effects of low concentration of METH on
GLUT1 function (Figure 2C). We noted that METH-
induced alteration in GLUT1 protein levels appeared to
be regulated at transcription level because actinomycin D
(Acd, transcription inhibitor, 100 ng/mL) prevented the
regulation of GLUT1 protein expression in 20 μMa n d
200 μM METH treated cells (Figure 3A-B). However,
METH elicited regulation of GLUT1 expression was not
affected by cycloheximide (Chx, translation inhibitor, 10
μg/mL).
METH administration inhibits glucose uptake in animal
model
To determine whether chronic administration of a mod-
erately high dose of METH can exert a similar effect to
that of high dose in cell culture, a daily dose of 15
mg/kg body weight was given to mice by i.p injection for
5-6 weeks. Then equimolar of [
3H]-glucose (2 μCi) and
unlabelled glucose was infused through the right com-
mon carotid artery as described in methods section. Our
data showed that 5-6 week administration of METH
almost completely inhibited glucose transport into the
frontal and occipital cortex of the brain (Figure 3C). ALC
protected the adverse effect of METH on glucose trans-
port, which was also observed in the mice behavior. In
that mice given the METH alone were inactive and
lethargic by week 5, whereas METH+ALC administered
mice were still active as the control mice.
Staining and co-localization of GLUT1 and vWF in
the brain capillaries (arterioles) sections indicated a
number of positive stained for GLUT1 and vWF within
the capillaries (Figure 4A a-c). Magnification of the indi-
vidual capillary revealed that the diameters of these
capillaries were 3-7 μms i z e ,a n da l s oG L U T 1a n dv W F
were localized mostly within the vascular tissue (both
luminal and abluminal regions of the capillaries) with
very minimal staining in the perivascular region (Figure
4A d-l). The decrease in glucose uptake correlated with
the diminished level of GLUT1 expression in the micro-
vessels of METH exposed mice. We also observed that
ALC effectively protected GLUT1 expression in micro-
vessels from chronic METH administration (Figure 4A c
and 4A j-l). To confirm the compartmentalization of
GLUT1 in brain microvessel (BBB) and in the brain tis-
sues (without vessels), we extracted protein from micro-
v e s s e l sa sw e l la sf r o mb r a i nt i s s u e sa n ds u b j e c t e dt o
Western blot analyses. METH-mediated decrease in
Figure 1 METH inhibits glucose uptake in hBEC.( A)D o s e
dependent Effect of METH on D-(2-
3H)-glucose uptake in hBECs for
24 hr. (B) Effect of METH (20 μM and 200 μM) on D-(2-
3H)-glucose
uptake in hBECs with or without GLUT1 inhibitor cytochalasin B (CB,
10 μM) and acetyl-L-carnitine (ALC, 200 μM) for 24 hr. (C) Effect of
METH on D-(2-
3H)-glucose uptake in hBECs at 24, 48 and 72 hr
exposure periods and compared with untreated control cells. *p <
0.05, **p < 0.01 statistically significant compared with controls.
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Page 3 of 13Figure 2 Effect of METH on GLUT1 expression in hBEC.( A) Immunocytochemical expression of GLUT1 (green) merged with von Willebrand
factor (vWF, red) and DAPI (blue) in hBECs. (B) Effect of METH (20 μM and 200 μM) on 55 kDa isoform GLUT1 protein levels in hBEC lysate
protein with different co-treatments for 24 hr. (C) Effect of METH (20 μM) on 55 kDa isoform GLUT1 protein levels in hBEC lysate protein with
different time periods and compared with 72 hr control cells. Both bar graphs show the results, which are expressed as ratio of GLUT1 to that of
a-actin bands and presented as the mean values (± SEM; n = 5). *p < 0.05, **p < 0.01 statistically significant compared with controls. Scale bar
indicates 40 μm in the panels of A.
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vessels correlated well with GLUT1 protein contents in
protein extracts from microvessels and in brain tissue
(Figure 4B-C). GLUT1 detected in protein extract
microvessels was predominantly a 55 kDa isoform,
whereas GLUT1 observed in protein extract from brain
tissue was mostly a 45 kDa isoform with a very weak
detection of 55 kDa isoform. The functional integration
of this structural difference is described in the discus-
sion section.
METH-induced inhibition of glucose uptake impairs BBB
integrity
To evaluate the role of glucose uptake on BBB integrity,
we examined the effects of METH and METH+CB on
the expression of the BBB tight junction (TJ) protein
occludin in intact brain microvessels. Immunohisto-
chemistry analysis demonstrated a diminished staining
of occludin with gap formation in brain microvessels
from 6 weeks administration of METH compared with
control (Figure 5A-B). Administration of the GLUT1
inhibitor CB alone (Figure 5C) or co-administration of
with METH (data not shown) for 7 days altered the
integrity of the BBB TJ protein, suggesting that efficient
glucose uptake and utilization by endothelial cells play a
pivotal role for proper maintenance of BBB integrity.
The duration of daily CB or METH+CB administration
was terminated after 7 days because the CB+METH
mice were showing sign of physical weakness even if
they were eating like the control mice. The staining of
occludin both in control and METH+ALC brain vessels
showed a sharp and continuous distribution of occludin
in intact brain microvessel indicating the protective
effects of ALC on BBB function (Figure 5D). Staining
for ZO-1 protein demonstrated a similar pattern but not
as distinct as that of occludin (data not shown). The
weak staining of ZO-1 in the intact microvessels was
attributed to the intracellular localization of ZO-1,
which acts as the anchoring protein for occludin and
claudin proteins. Alterations of occludin and ZO-1
protein levels were also evaluated by Western blot in pro-
tein extract from primary hBEC culture. We observed
that both 20 μMa n d2 0 0μM of METH exposure for 24
hr reduced the levels of occludin and ZO-1 proteins in a
dose-dependent manner compared with control cells
(Figure 5E-F). ALC protected the effects of METH on
occludin and ZO-1 protein levels. Treatment of cells with
CB (inhibitor of GLUT1) completely down-regulated the
levels of occludin and ZO-1 (data not shown), suggesting
that glucose uptake by brain endothelial cells was
essential for maintenance of BBB integrity.
Acute and chronic METH exposure impairs BBB function
To correlate the alterations of the BBB tight junction
proteins, we evaluated the loss of functional integrity of
the BBB by permeability and trans-endothelial electrical
resistance (TEER) assays. In the in vivo studies, both
acute (Figure 6A-B) and chronic (Figure 6C-D) exposure
to METH (15 mg/kg body weight) increased the perme-
ability of small molecular weight NaFl and large molecu-
lar weight tracer EB across the BBB compared with
respective controls. Treatment of CB exacerbated the
Figure 3 METH inhibits glucose uptake in hBECs and animal
model.( A-B) Regulation of GLUT1 levels by actinomycin D (Acd,
transcription inhibitor, 100 ng/mL) and cycloheximide (Chx,
translation inhibitor, 10 μg/mL) in hBECs exposed to METH for 24 hr.
The results show the regulation of GLUT1 was affected at
transcription level. Results are expressed as ratio of GLUT1 to that of
a-actin, and presented as the mean values (± SEM; n = 3). (C) Effect
of chronic METH administration (15 mg/kg body weight) on glucose
uptake in vivo. *Statistically significant, *p < 0.05, **p < 0.01
compared with control.
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(Figure 6A-D), suggesting that glucose uptake and meta-
bolism play a crucial role for BBB functional integrity. To
avoid contamination of tracers from microvessels, we
carefully removed the microvessels from brain tissues.
Thus, the dye tracers that we detected had penetrated
into the brain due to BBB leakage. Our data suggest that
ALC protected against METH-induced BBB permeability
both in acute and in chronic conditions.
The METH-induced increase in permeability was also
confirmed by a huge decrease in TEER of the BBB,
which was further abrogated by addition of CB (Figure
6 E ) .W eo b s e r v e dt h a tb o t h2 0μMa n d2 0 0μMM E T H
produced a significant reduction in electrical resistance,
which was prevented by ALC. The decrease in TEER
appeared gradually following METH or CB application,
which culminated to a partial loss of monolayer integ-
rity. The effect of CB and METH on TEER suggests that
glucose uptake and constant energy regulation play an
important role for maintaining the BBB integrity and
barrier function. To support the argument, we further
examined the survival of brain endothelial cells that
were cultured in DMEM/F-12 glucose-free media with
or without METH exposure for 48 hr. Culture of
endothelial cells in normal DMEM/F-12 media with or
without METH exposure was used as positive control,
in which METH affected the viability of the cells. Viabi-
lity of cells was significantly affected by the absence of
glucose, which was further abrogated by the presence of
100 μM METH in the culture (Figure 7). Supplementa-
tion of pyruvate in glucose-free culture media does-
dependently mitigated the survival of cells from the
adverse effects of METH and lack of glucose. These
results suggest that availability of energy substrate is
very essential for survival endothelial cells and mainte-
nance of the BBB integrity. METH appears to disrupt
endothelium function by impairing GLUT1 function (i.e.
decrease in glucose uptake) and perhaps glycolysis
Figure 4 METH exposure impairs GLUT1 expression in microvessels and brain tissues.( A)E x p r e s s i o no fG L U T 1( g r e e n )i nm i c r o v e s s e l
capillaries of brain tissue section in control (a), 200 μM METH (b) and 200 μM METH+200 μM ALC (c). The expression of GLUT1 (green) merged
with vWF (red) in enlarged view of a single capillary is shown in control (d-f), 200 μM METH (g-i) and 200 μM METH+200 μM ALC (j-l).( B)
Expression of 55 kDa isoform GLUT1 protein in brain microvessels and (C) levels of 45 kDa isoform GLUT1 protein in brain tissue protein extract.
Bar graphs show the results, which are expressed as ratio of GLUT1 to that of a-actin bands and presented as the mean values (± SEM; n = 3).
**Statistically significant (p < 0.01) compared with controls. Scale bar indicated 20 μm in panels of a-c and 5 μm (shown in d) in panels of d-l.
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chemical pathway for converting pyruvate to energy pro-
duction seems to be unaffected. The dose-dependent
protective effects of pyruvate and enhanced recuing
effect of 2.0 mM pyruvate in the presence of ALC sup-
ported the notion that Krebs cycle within endothelium
was still active.
Discussion
We found that a high concentration of METH (200 μM)
significantly decreased the rate of glucose uptake and
glucose transporter protein-1 (GLUT1) expression. This
was followed by impairment of BBB integrity as indi-
cated by the increased permeability of the molecular
tracers in an in vivo s t u d i e sa n dad e c r e a s ei nt r a n s -
endothelial electrical resistance in primary hBEC culture.
Interestingly, a low level of METH (20 μM) insignifi-
cantly elevated both glucose uptake and GLUT1 protein
expression in hBECs in acute but not in chronic condi-
tion. We demonstrated here for the first time that inter-
ference of glucose uptake and transport at the brain
endothelium by chronic METH exposure lead to BBB
dysfunction. METH doses of 200 μM in cell culture and
15 mg/kg body weight in animal study are considered
moderately high concentrations and our low dose is
close to the blood of recreational users of METH (20-40
mg/kg) [30,31]. The high dose users, who normally
administer 100-1000 mg/kg may be equivalent to
Figure 5 Disruption of GLUT1 affects the integrity of BBB.( A-D) Immunohistochemistry of occludin in intact brain microvessels of control
(A), METH (15 mg/kg body weight) (B), CB (20 μM) (C) and METH+ALC (ALC = 200 μM) (D) treated mice. (E) Western blot analysis of tight
junction proteins, occludin (a 65 kDa protein) and (F) ZO-1 (225 kDa protein) in hBECs. Bar graphs show the results that are expressed as ratio of
occludin or ZO-1 to that of a-actin bands and presented as the mean values (± SEM; n = 4). Scale bar indicates 20 μm in A-D.
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metabolized to amphetamine, 4-hydroxymeth-ampheta-
mine and norephedrine [32,33], the levels of METH
detected in the circulation represent the 30-50% un-
metabolized methamphetamine.
Daily chronic intraperitoneal injection of METH (15
mg/kg body weight) in mice for 5-6 weeks almost com-
pletely inhibited the glucose transport across the BBB,
which validated our in vitro findings. The METH-
induced decrease in glucose transport across the BBB
correlated with the diminished levels of GLUT1 protein
expression in brain microvessels (the primary tissue
components of BBB). It was interesting to find the exis-
tence of two distinct isoforms of GLUT1 at the BBB
interface (microvessels) with a molecular size of 55 kDa
and in the brain tissue with a molecular size of 45 kDa.
Expression of these GLUT1 isoforms proteins was
reduced by METH administration. Similar to these find-
ings, it has been reported that 55 kDa GLUT1 is loca-
lized specifically in endothelial cells, whereas the 45 kDa
isoform is expressed in the perivascular end-feet of
astrocytes [24,25]. Functionally, the 55 kDa isoform is
highly glycosylated, while the 45 kDa is the less glycosy-
lated isoform [34]. We hypothesize that due to the
dynamic nature of the BBB, the GLUT1 at this interface
is mostly in the active N-glycosylated form ready to
transport glucose from the peripheral circulation into
the brain. The packaging of glucose into the transporter
protein for delivery into the brain is possible only when
GLUT1 is enzymatically glycosylated by acetylglucosa-
mine. We suggest that once the GLUT1 (55 kDa) is
translocated onto the abluminal side of the BBB, it
releases the glucose at the perivascular region to the
end-feet of astrocytes and neurons. Here, GLUT1
becomes mostly in the non-glycosylated 45 kDa isoform.
Figure 6 METH and CB increase BBB permeability and decrease
TEER. (A-D) Permeability of sodium fluorescein (NaFl, 5 μM) or
Evans Blue (EB, 5 μM) across the BBB in acute METH exposure (A-B)
and chronic METH administration (15 mg/kg body weight) (C-D).
(E) Trans-endothelial electrical resistance (TEER) of hBECs monolayers
following treatment with various test compounds (n = 2). TEER was
measured at 400 Hz in 10 min intervals for 12 hours. The treatments
were started after stable resistance was reached for 1 hr.
*Statistically significant (*p < 0.05, **p < 0.01 and ***p < 0.001)
compared with controls.
Figure 7 Pyruvate protects glucose-deficient and METH
induced cell dead. Confluent hBECs cultured in 96 well plates
(20000 cells/well) in normal (+ glucose) or glucose-free (-glucose)
media were exposed to 100 μM METH for 48 hr, and were analyzed
for cell viability assay. Untreated in (+) glucose is a positive control
and in (-) glucose is a negative control. Supplementation of
pyruvate (PV) in glucose-free cell culture showed dose-dependent
protection from METH and glucose deficiency. *Statistically
significant (*p < 0.05, and ***p < 0.001) and
#p < 0.05,
##p < 0.01
and
###p < 0.001 from (-) glucose+METH condition (fourth bar).
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that we detected in protein extract from brain tissue
may be a contamination of internal arterial vessels. Thus
glycosylation of GLUT1 is crucial for functional integra-
tion and structural preservation [24].
We showed that METH-elicited inhibition of glucose
uptake and suppression of GLUT1 protein at the inter-
face were accompanied by disruption of BBB integrity. It
was evident that decrease in tight junction (TJ) proteins
by METH exposure led to enhanced permeability of dye/
fluorescein tracers across the BBB and a huge decrease in
trans-endothelial electrical resistance of the BBB. The
METH-induced increase in permeability and decrease in
electrical resistance across the BBB has been attributed
t ot h et o x i c i t yo fM E T Hb ys o m ei n v e s t i g a t o r s
[23,35-37]. Here we attributed to the impairment of glu-
cose uptake and transport at the endothelium as one of
the factors for BBB dysfunction. The rationale was that
co-administration of CB exacerbated the effects of
METH on TJ protein expression, BBB permeability and
almost completely abrogated the BBB electrical resis-
tance. In order to meet the constant energy demand of
the dynamic BBB function, it is possible that there is
synergistic interaction between GLUT1 and TJ proteins.
As such, interference in endothelial glucose uptake and
GLUT1 function by METH is likely to disrupt TJ protein
integrity and BBB function. The question of whether
such a defective BBB function will enhance passive diffu-
sion of glucose into the brain interstitial fluid (ISF) may
require further investigation. However, based on available
information, BBB damage and defective in blood-brain
barrier GLUT1 function seem to decrease glucose levels
in the brain, similar to what we observed here. For exam-
ple, in neurological diseases such as aging-related Alzhei-
mer disease [38,39] and De Vivo disease/syndrome
[40,41], where BBB disruption and GLUT1 defect were
clearly observed, the levels of glucose in brain interstitial
fluid were decreased from the normal values. That is
because transport of glucose across the BBB into the
brain interstitial fluid is exclusively an endothelium
GLUT1-dependent and gradient-independent process
[42,43]. Interestingly, alteration GLUT1 at the BBB has
been shown to affect the facilitated entry of glucose and
efflux of glucose from the brain rather than passive influx
of glucose into the brain [40,43].
Glucose is the main source of energy in the brain.
Therefore inhibition of glucose transport across the BBB
endothelium by METH is expected to disrupt the homeos-
tasis of glucose metabolism and energy demands of the
brain cells, such as the dynamic BBB function. In part, this
may explain as to why METH abusers exhibit impairment
of glucose metabolism in various brain regions such as the
frontal white matter [44], the striatum and thalamus
[45], the limbic and paralimbic region [46], and in rat
hippocampus [47]. We propose that impairment of
GLUT1 function by METH exposure affects the rate of
glucose uptake and metabolism (glycolysis) in brain
endothelium, resulting in disruption of BBB integrity and
endothelial cell death. However, METH exposure did not
seem to affect the Krebs cycle because pyruvate oxidation
appears to be active and normal in endothelial cells
exposed to 100 μM METH. This finding suggests that the
primary enzyme pyruvate dehydrogenase, which converts
pyruvate to acetyl-coenzyme A was not severely damage
by METH exposure. Further, stabilization of glucose
uptake and GLUT1 protein levels by ALC from METH
exposure may provide evidence for involvement of ALC in
glucose metabolism. It is possible that ALC stabilizes the
glycosylation of GLUT1 protein at the brain endothelium
by donating an acetyl group to glucosamine so as to keep
the acetylglucosamine functional. In this way ALC may be
able to maintain the structure and functional integration
of GLUT1 glycosylation at the BBB and recycle the less
glycosylated GLUT1 in the neurovascular compartment.
The question of whether inability of BBB to deliver normal
glucose levels into the brain during METH abuse has
impact on neurodegeneration is not within scope of the
present study. It will require further comprehensive inves-
tigations to uncover this important issue both in vitro and
in vivo studies.
Conclusions
Our data indicate that METH mediated impairment of
glucose uptake and transport at the brain endothelium
disrupts the BBB function for efficient delivery of glu-
cose into the brain. Thus, destruction of GLUT1 func-
t i o na tt h ee n d o t h e l i u mm a yb eap o s s i b l eu n d e r l y i n g
mechanism for BBB damage.
Methods
Reagents
We purchased the antibodies to GLUT1 from Abcam
(Cambridge, MA), antibodies to occludin and ZO-1
from Zymed (Invitrogen, Carlsbad, CA), and antibody to
a-actin from Millipore (Billerica, MA). All secondary
alexa fluor antibodies were purchased from Invitrogen.
D-(2-
3H)-glucose (5 mCi, 185 MBq) was purchased
from PerkinElmer Life and Analytical Sciences (Wal-
tham, MA). Cytochalasin B (CB), cycloheximide (Chx),
actinomycin D (Acd) and acetyl-L-carnitine (ALC) were
purchased from Sigma-Aldrich (St. Louis, MO).
hBEC culture
Primary human brain endothelial cells (hBECs) were
obtained from Dr. Persidsky’s Lab, Temple University
School of Medicine, and hBECs were cultured as
described previously [48]. Briefly, all cell culture plates
and glass cover slips were pre-coated with type 1 rat-tail
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Page 9 of 13collagen (0.09 mg/mL in double distilled sterile water),
aspirated the excess collagen and dried the plates over-
night in sterile hood. For glucose uptake and viability
assays, cells were cultured in 96-well plates (20,000
cells/well), for immunohistochemistry cells were plated
on 12-well glass cover slips (40,000 cells/well) and for
protein extractions cells were cultured in T75 cm
2 flasks
(1 × 10
6 cells/flask). DMEM/F-12 media containing
10 mM Hepes, 13 mM sodium bicarbonate (pH 7), 10%
fetal bovine serum, penicillin and streptomycin (100 μg/ml
each, Invitrogen) were used for cell culture. Cell culture
media was changed every 3 days until tight monolayers
were formed in about 6-8 days.
In vitro glucose uptake
Following the modified method of Takakura [49], D-(2-
3H)-glucose uptake was performed on hBECs cultured in
96 well plates. Cells were exposed to 20 μM and 200 μM
METH for 24 hr in the presence or absence of 10 μM
cytochalasin B (CB, 10 mM stock was dissolved in
DMSO) or 200 μM ALC in a CO2 incubator. Cells were
then incubated overnight in glucose-free DMEM/F-12
media containing equimolar of D-(2-
3H)-glucose
(1.0 μCi) and non-radiolabeled glucose. After washing off
the excess
3H-glucose with phosphate saline buffer (PBS),
cellular protein was precipitated with 10% TCA at 4°C
for 15 min. Following the manufacturer’si n s t r u c t i o n ,
precipitated proteins were transferred onto a 96 well
nitrocellulose filter using the Unifilter-96 well Harvester
(PerkinElmer, Waltham, MA). Using the Beckman 96
well plate reader, radioactivity was measured by b-top
counter. METH concentrations of 20 and 200 μMw e r e
derived from dose- and time-dependent toxicity assay (5,
10, 20, 50, 100, 200, 500 and 1000 μMo fM E T Hf o r2 4 -
72 hrs), in which 20 μM had no cell toxicity effects while
200 μM of METH showed about 20% cell death after 48
hr exposure. ALC concentration of 200 μMw a sd e r i v e d
from dose-dependent study of 50-5000 μMo nc e l lv i a b i -
lity. Concentration of CB higher than 20 μM was toxic to
hBECs (derived from 1 - 100 μM CB concentrations).
Cell viability assay
Cell viability on hBEC was determined by 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. The assay is based on the cleavage of
yellow tetrazolium salt to purple formazan crystals by
metabolically active cells. Briefly, cells were cultured in
96-well microtiter plates up to 90-100% confluent. Then
the cells were treated for 48 hr in the presence or
absence of METH or Pyruvate, or in combination of
METH+pyruvate in glucose-free media in culture. Cells
were then incubated at 37°C for 45 minutes after adding
100 μl MTT (5 mg/ml MTT in 10% FBS in 1× PBS).
Then 100 μl DMSO was added just after aspirating the
MTT solution and the plates were incubated at room
temperature for 15 min. Absorbance of the purple
formazan was detected by a microtiter plate reader at
490 nm wavelength.
Immunfluorescent detection
For immunocytochemistry, the hBECs were cultured on
glass cover slips in 12 well flasks until 80-100% conflu-
ent. Cells were then treated with 20 μMa n d2 0 0μM
METH with and without CB (10 μM) or ALC (200 μM)
for 24 hours. For immunohistochemistry, tissue sections
(8 μm thickness) were derived from chronic METH,
METH+ALC or pair-fed control mice. Cells and tissue
sections were washed with PBS, fixed in acetone-metha-
nol (1:1 v/v) fixative, blocked the cellular antigen with
3% bovine serum albumin at room temperature for 1 hr
in the presence of 0.4% Triton X-100, and incubated
with respective primary antibodies such as mouse anti-
GLUT1 (1:250 dilution), rabbit anti-von Willebrand fac-
tor (vWF) (1:150 dilution), rabbit anti-occludin (1:250
dilution) and rabbit anti-ZO-1 (1:250 dilution) overnight
at 4°C. After washing with PBS, cells/tissue sections
were incubated for 1 hr with secondary antibody: anti-
mouse-IgG Alexa Fluor 488 for GLUT1; anti-rabbit-IgG
Alexa Fluor 594 for vWF; anti-rabbit-IgG Alexa Fluor
488 for occludin and ZO-1. Cover slips were then
mounted onto glass slides with immunomount contain-
ing DAPI (Invitrogen), and fluorescence microphoto-
graphs were captured by fluorescent microscopy (Eclipse
TE2000-U, Nikon microscope, Melville, NY) using NIS
elements (Nikon, Melville, NY) software. GLUT1
expression was also analyzed in brain microvessels that
were surgically dissected under microscope.
Western blotting
The hBECs cultured in T-75 cm
2 flasks were lysed with
CellLytic-M (Sigma) for 30 min at 4°C, centrifuged at
14000 g, and then total cell lysates protein concentra-
tions were estimated by BCA (Thermo Scientific, Rock-
ford, IL). We loaded 20 μg protein/lane and resolved the
various molecular weight proteins by SDS-PAGE on gra-
dient gels (Thermo Scientific) and then transferred the
protein onto nitrocellulose membranes. After blocking,
membranes were incubated for overnight with polyclo-
nal antibody against mouse anti-GLUT1 protein (1:1000,
Abcam, Cambridge, MA), rabbit anti-occludin antibody
(1:250 dilution) and rabbit anti-ZO-1 antibody (1:250
dilution) at 4°C followed by 1 hr incubation with horse-
radish peroxidase conjugated secondary antibodies.
Immunoreactive bands were detected by West Pico che-
miluminescence substrate (Thermo Scientific). Data
were quantified as arbitrary densitometry intensity units
using the Gelpro32 software package (Version 3.1,
Media Cybernetics, Marlow, UK).
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To determine the integrity of BBB function, changes in
trans-endothelial electrical resistance (TEER) across the
BBB were analyzed by a highly sensitive 1600R ECIS
system (Applied Biophysics, Troy, NY). The ECIS sys-
tem provides real-time monitoring of changes in TEER.
In brief, hBECs at 20000 cells/well were plated on col-
lagen type I coated 8W10E electrode arrays (Applied
Biophysics). Once tight cell monolayers were formed,
stable TEER value was monitored for 1 hr prior to treat-
ment of cell monolayers with 20 μM and 200 μM
METH in the presence or absence of CB or ALC
followed by 10 hr recording of TEER at 400 hz with
10 min intervals. Confluent cell monolayers demon-
strated baseline TEER readings of 1100 to 1200 Ω.cm2.
In vivo glucose transport assay
Five-week old male C56/BL-6J mice purchased from Jack-
son Laboratory (Bar Harbor, ME) were maintained in ster-
ile cages under pathogen-free conditions in accordance
with institutional ethical guidelines for care of laboratory
animals, National Institutes of Health (NIH) guidelines,
and the Institutional Animal Care Use Committee. On the
basis of weight matched, initially mice were grouped into
control, METH and METH+ALC and they were fed the
normal Lieber-DeCarli liquid-diet (Dyets, Inc. Bethlehem,
PA) for 5-6 weeks. ALC was mixed in the liquid diet
(1.0 mg/mL) and METH (15 mg/kg body weight) was
administered daily by i.p injection for 5-6 weeks. After
week 5 pair feeding of liquid-diet and monitoring the body
weights, the control, METH and METH+ALC mice were
anesthetized with ketamine (100 mg/kg body weight) and
xylazine (10 mg/kg body weight), and equimolar of 2-
3H-
glucose (2 μCi) and unlabelled glucose in 100 μl of saline
were infused through the right common carotid artery.
After 1 hr, mice were euthanized and then microvessels
were removed and tissues were dissected from different
brain regions. Known tissue weights were homogenized
with 100 μl of Krebs-Ringer phosphate-HEPES (KRPH)
buffer, centrifuged at 12,000 rpm for 15 min, and 20 μlo f
supernatants from each condition was mixed with 4 mL of
scintillation fluid. The levels of 2-
3H-glucose in the
samples were detected by liquid scintillation counter
(Beckman) along with a standard curve of 2-
3H-glucose
that was run in parallel. Results were extrapolated from
the standard curve and data were expressed as counts per
minutes (cpm) per milligram tissue weight.
In vivo BBB permeability assay
Using the sodium fluorescein (NaFl) and Evans Blue
(EB) tracer dye mixtures (5 μM each), the effect of
METH on BBB permeability was examined in acute and
chronic animal model following an established method
[50]. In acute studies, mice were anesthetized, infused
with 100 μlo f2 0 0μMo fA L Co r2 0μMo fC Bo r
200 μM of METH via the common carotid artery. ALC
was infused 30 min prior to METH infusion. After 1 hr
of CB and METH infusion, NaFI/EB mixture was
infused into the CCA and waited for another 30 min
before euthanizing the animals. In chronic studies, the
controls, METH (15 mg/kg body weight) and METH
+ALC (ALC, 1.0 mg/mL) were given for 5-6 weeks as in
glucose uptake assay. Daily i.p infusion of CB (20 μM)
or CB+METH lasted for 7 days only because mice that
received the CB+METH injection were getting weak by
then. Mixture of NaFl/EB dyes was then infused directly
into the right carotid artery as in acute studies. After
decapitating, brains were removed, dissected, weighed
and homogenized in 600 μl 7.5% (w/v) trichloroacetic
acid (TCA). Resulting suspensions were divided into two
aliquots (300 μl each). One aliquot was neutralized with
50 μl 5 N NaOH and measured by fluorimetry on a
GENios microplate reader (excitation 485 nm, emission
535 nm) for NaFI determination. The other aliquot was
centrifuged 10 min at 10000 rpm, 4°C, and the superna-
tant was measured by absorbance spectroscopy at
620 nm for EB determination. Standard curve was
constructed by serial dilutions of a standard EB/NaFl
solution in 7.5% TCA.
Statistical analysis
Values are expressed as the mean ± SEM. Within an
individual experiment, each data point was deter-
mined from three to five replicates. Statistical analy-
sis of the data used GraphPad Prism V5 (Sorrento
V a l l e y ,C A ) .C o m p a r i s o n sbetween samples were per-
formed by one-way ANOVA with Dunnett’sp o s t - h o c
test. Differences were considered significant at
Pv a l u e s≤ 0.05.
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